L
Luisa Rusconi
Researcher at Pasteur Institute
Publications - 20
Citations - 1702
Luisa Rusconi is an academic researcher from Pasteur Institute. The author has contributed to research in topics: Aurora inhibitor & Kinase. The author has an hindex of 14, co-authored 20 publications receiving 1552 citations.
Papers
More filters
Journal ArticleDOI
The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation
Sonja Baumli,Graziano Lolli,Edward D. Lowe,Sonia Troiani,Luisa Rusconi,Alex N. Bullock,Judit É. Debreczeni,Stefan Knapp,Louise N. Johnson +8 more
TL;DR: The structures of the CDK9/CycT1 and free cyclin T2 are determined to understand the regulation of a transcriptional CDK by its cognate cyclin and shows flexibility that may be important for the interaction of this region with HIV TAT and HEXIM.
Journal ArticleDOI
PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
Patrizia Carpinelli,Roberta Ceruti,Maria Laura Giorgini,Paolo Cappella,Laura Gianellini,Valter Croci,Anna Degrassi,Gemma Texido,Maurizio Rocchetti,Paola Vianello,Luisa Rusconi,Paola Storici,Paola Zugnoni,Claudio Arrigoni,Chiara Soncini,Cristina Alli,Veronica Patton,Aurelio Marsiglio,Dario Ballinari,Enrico Pesenti,Daniele Fancelli,Jürgen Moll +21 more
TL;DR: It is concluded that PHA-739358, which is currently tested in clinical trials, has great therapeutic potential in anticancer therapy in a wide range of cancers.
Journal ArticleDOI
Discovery of Entrectinib: A New 3-Aminoindazole as a Potent Anaplastic Lymphoma Kinase (Alk), C-Ros Oncogene 1 Kinase (Ros1), and Pan-Tropomyosin Receptor Kinases (Pan-Trks) Inhibitor.
Maria Menichincheri,Elena Ardini,Paola Magnaghi,Nilla Avanzi,Patrizia Banfi,Roberto Bossi,Laura Buffa,G. Canevari,Lucio Ceriani,Maristella Colombo,Luca Corti,Daniele Donati,Marina Fasolini,Eduard R. Felder,Claudio Fiorelli,Francesco Fiorentini,Arturo Galvani,Antonella Isacchi,Andrea Lombardi Borgia,Chiara Marchionni,Marcella Nesi,Christian Orrenius,Achille Panzeri,Enrico Pesenti,Luisa Rusconi,Maria Beatrice Saccardo,Ermes Vanotti,Ettore Perrone,Paolo Orsini +28 more
TL;DR: Entrectinib resulted to be strictly potent on the closely related tyrosine kinases ROS1 and TRKs recently found constitutively activated in several tumor types.
Journal ArticleDOI
PHA-680632, a Novel Aurora Kinase Inhibitor with Potent Antitumoral Activity
Chiara Soncini,Patrizia Carpinelli,Laura Gianellini,Daniele Fancelli,Paola Vianello,Luisa Rusconi,Paola Storici,Paola Zugnoni,Enrico Pesenti,Valter Croci,Roberta Ceruti,Maria Laura Giorgini,Paolo Cappella,Dario Ballinari,Francesco Sola,Mario Varasi,Rodrigo Bravo,Jurgen Moll +17 more
TL;DR: PHA-680632 is the first representative of a new class of Aurora inhibitors with a high potential for further development as an anticancer therapeutic, and kinetic studies on its inhibition in vitro and in vivo show that phosphorylation of histone H3 is a good biomarker to follow activity of PHA- 680632.
Journal ArticleDOI
Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 Kinase
Riccardo Colombo,Marina Caldarelli,Milena Mennecozzi,Maria Laura Giorgini,Francesco Sola,Paolo Cappella,Claudia Perrera,Stefania Re Depaolini,Luisa Rusconi,Ulisse Cucchi,Nilla Avanzi,J.A. Bertrand,Roberto Bossi,Enrico Pesenti,Arturo Galvani,Antonella Isacchi,Francesco Colotta,Daniele Donati,Jürgen Moll +18 more
TL;DR: NMS-P715 is reported, a selective and orally bioavailable MPS1 small-molecule inhibitor, which selectively reduces cancer cell proliferation, leaving normal cells almost unaffected, and inhibits tumor growth in preclinical cancer models.